AP NEWS

Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists

October 12, 2018

TOKYO--(BUSINESS WIRE)--Oct 12, 2018--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it released a disease awareness anime about rheumatoid arthritis dubbed in English and subtitled in Chinese, Korean, French and Spanish, celebrating World Arthritis Day on October 12.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005989/en/

(Graphic: Business Wire)

Rheumatoid arthritis is an autoimmune disease that most commonly develops in women aged from 30 to 59. The number of patients is estimated to be 0.7 million in Japan and 23 million in the world*. The disease causes destruction of the joints and bones and deformation of hands and feet, which may significantly affect daily lives. However, with recent treatment advances an increasing number of people with the disease can control joint swelling and pain, as well as continue daily activities like housekeeping and hobbies, if they visit specialized medical centers early and receive appropriate treatment. *Report by Study Committee on Rheumatoid Arthritis and Allergy; ( http://www.mhlw.go.jp/stf/houdou/2r9852000001nfao-att/2r9852000001nfdx.pdf ) and WHO Global Burden of Disease Report (table 7, page 32) 2004; ( http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf )

Chugai has continuously emphasized the importance of early treatment of rheumatoid arthritis and promoted a better understanding through a short film titled “Mother’s Lipstick” (awarded 2016 Cannes Lions Bronze) and a music video titled “With A Wish” released by a singer, Mina Ganaha.

Under the concept of “contribute to the medical community and people’s health around the world by expanding awareness of rheumatoid arthritis among the general public as well as patients and their families,” we have decided to release a disease awareness film by means of anime, one of the icons of Japanese culture. With this movie, we aim to appeal to a broad age range, including the younger generation aged between 10 to 29, about the importance of “early detection”, “early treatment” and “medical care provided by rheumatologists”.

Tatsunoko Production Co., Ltd., a company that has introduced Japan’s leading anime series including “Yatterman” and “The Genie Family” throughout the world, was responsible for character design and production. Ayana Taketatsu, a voice actress who has over one million followers on Twitter, and Kayoko Ohkubo, a comedienne who herself has experienced rheumatoid arthritis, voiced the main characters.

Chugai is continuously committed to promoting disease awareness activities leading to trust and appreciation from all stakeholders including patients, their families, and healthcare professionals, aiming at contributing to the medical community and people’s health around the world.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis). Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005989/en/

CONTACT: For Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group, Corporate Communications Dept.,

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail:pr@chugai-pharm.co.jp

***

For European media

Chugai Pharma France SAS

Nathalie Leroy

Tel: +33-1-56-37-05-21

E-mail:pr@chugai.eu

***

For Taiwanese media

Chugai Pharma Taiwan Ltd.

Susan Chou

Tel: +886-2-2715-2000

E-mail:pr@chugai.com.tw

***

For Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group, Corporate Communications Dept.,

Toshiya Sasai

Tel: +81-3-3273-0554

E-mail:ir@chugai-pharm.co.jp

KEYWORD: EUROPE ASIA PACIFIC SOUTH KOREA TAIWAN JAPAN

INDUSTRY KEYWORD: ENTERTAINMENT MUSIC HEALTH BIOTECHNOLOGY FILM & MOTION PICTURES CELEBRITY PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE

SOURCE: Chugai Pharmaceutical Co., Ltd.

Copyright Business Wire 2018.

PUB: 10/12/2018 12:30 AM/DISC: 10/12/2018 12:30 AM

http://www.businesswire.com/news/home/20181011005989/en

AP RADIO
Update hourly